K-numberK243376
Device nameuAngio AVIVA CX
ApplicantShanghai United Imaging Healthcare Co., Ltd.
Product codeOWB
Device classClass II
Decision dateApr 28, 2025
DecisionSubstantially Equivalent
Regulation892.1650
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The uAngio AVIVA CX is an angiographic X-ray system designed to provide image guidance in diagnostic, interventional, and surgical procedures. It can perform cardiac angiography, neuro-angiography, vascular and non-vascular angiography, rotational angiography, and whole body radiographic/fluoroscopic procedures across all human patient ages.

Technological characteristics

The proposed device matches the predicate (Azurion R2.1) in most specifications including 100 kW generator power, 1000 mA at 100 kV, 48 cm diagonal field of view, and identical image acquisition protocols. Minor differences include three focal spots (0.4, 0.6, 1.0 mm) versus two on the predicate, slightly improved pixel pitch (150 μm vs 154 μm), higher patient table weight capacity, and additional software features (uSpace camera-assisted recognition and uLingo voice control).

Test standards cited

Compliance demonstrated with ANSI/AAMI ES60601-1:2005/A2:2021, ANSI/AAMI/IEC 60601-1-2:2014/A1:2021, IEC 60601-1-3:2021, IEC 60601-2-54:2022, IEC 60601-2-43:2022, IEC 60601-2-28:2017, and IEC 60825-1:2014. Non-clinical bench testing included Cone Beam CT performance, image registration fusion, DSA, 3D Roadmap, and software algorithm validation.

Substantial equivalence argument

The device has identical classification, intended use, indications, and primary technical specifications as the predicate Azurion R2.1. Differences such as an additional focal spot, improved pixel pitch, and enhanced patient table capacity either improve performance or broaden applicability without introducing new safety or effectiveness concerns. Novel software features (uSpace and uLingo) are ancillary enhancements controlled by user triggering with hardware collision prevention, and comprehensive testing demonstrates these do not adversely affect safety or essential performance. Clinical image evaluation confirmed diagnostic quality across head, cardiac, body, and extremity procedures.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →